Full Press Release Details
CureVac Swiss AG Initiates Rolling Submission Process for mRNA-based
COVID-19 Vaccine Candidate, CVnCoV, with Swissmedic
T BINGEN, Germany/ BOSTON, USA - April 19, 2021 -
The CureVac Swiss AG, the Swiss subsidiary of CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of
transformative medicines based on messenger ribonucleic acid (mRNA), today announced initiation of a rolling submission for CVnCoV, the
company's mRNA based COVID-19 vaccine candidate, for the use in Switzerland. The application for authorization was submitted to
Swissmedic, the country's authority responsible for the authorization and supervision of therapeutic products including vaccines.
CureVac has already provided the first data package on CVnCoV,
its COVID-19 vaccine candidate. Swissmedic will review these data regarding the standards of quality, safety and efficacy in
consideration of the potential authorization for use of the CureVac vaccine candidate in Switzerland. With this process the time to
authorization can be reduced.
"Switzerland is an important market for CureVac not only with
regards to CVnCoV", says Antony Blanc Chief Business Officer (CBO) & Chief Commercial Officer (CCO). "Along with Germany
and Austria, Switzerland represents one of the three countries for which CureVac holds exclusive commercialization rights for program
products in the context of CureVac's broad GSK partnership in vaccines for infectious diseases as well as second-generation vaccines
for COVID-19. After having established a legal entity in Basel in March 2021, we now took the next key step in preparing the timely access
to Switzerland following our ongoing efforts for the European Union territory."
In early February the Swiss federal government and CureVac have signed
a contract for the supply of five million vaccine doses. The contract is based on
the delivery agreement between the European Commission and the company.
CureVac's COVID-19 vaccine candidate is currently in late-stage
clinical testing. The pivotal Phase 2b/3 study (HERALD), initiated on December 14, 2020, has successfully completed recruitment, with
currently about 40,000 participants in Latin America and in Europe. In February 2021, the Company started a
rolling submission with the European Medicines Agency (EMA) for CVnCoV and, subject to the clinical trial results, expects the
potential authorization for use in the EU in the second quarter of 2021.
CureVac began development of
its mRNA-based COVID-19 vaccine candidates in January 2020. The vaccine candidate chosen first for clinical development, CVnCoV, is
an optimized, non-chemically modified mRNA, encoding the prefusion stabilized full-length spike protein of the SARS-CoV-2 virus, and
formulated within Lipid Nanoparticles (LNPs). Phase 1 and 2a clinical trials of CVnCoV began in June and September 2020,
respectively. Phase 1 interim data reported in November 2020 showed that CVnCoV was generally well tolerated across all tested doses
and induced strong antibody responses in addition to first indication of T cell activation. The quality of immune response was
comparable to recovered COVID-19 patients, closely mimicking the immune response after natural COVID-19 infection. In December 2020,
CureVac initiated a pivotal Phase 2b/3, the HERALD study, with a 12 g dose of CVnCoV. In February 2021, CureVac initiated
a rolling submission with the European Medicines Agency (EMA) for CVnCoV.
CureVac is a global biopharmaceutical
company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise in developing and optimizing the versatile
biological molecule for medical purposes. The principle of CureVac's proprietary technology is the use of non-chemically modified mRNA
as a data carrier to instruct the human body to produce its own proteins capable of fighting a broad range of diseases. Based on its
proprietary technology, the Company has built a deep clinical pipeline across the areas of prophylactic vaccines, cancer therapies, antibody
therapies, and the treatment of rare diseases. CureVac had its initial public offering on the New York Nasdaq in August 2020. It is headquartered
in T bingen, Germany, and employs more than 600 people at its sites in T bingen, Frankfurt, and Boston, USA. Further information
can be found at www.curevac.com.
CureVac Media Contact
Thorsten Sch ller, Vice President Communications
CureVac, T bingen, Germany
T: +49 7071 9883-1577
CureVac Investor Relations Contact
Dr. Sarah Fakih, Vice President Investor Relations
CureVac, T bingen, Germany
T: +49 7071 9883-1298
M: +49 160 90 496949
Forward-Looking Statements
This press release contains statements that constitute
"forward looking statements" as that term is defined in the United States Private Securities Litigation Reform Act of
1995, including statements that express the opinions, expectations, beliefs, plans, objectives, assumptions or projections of
CureVac (the "company") regarding future events or future results, in contrast with statements that reflect historical
facts. Examples include discussion of the potential efficacy of the company's vaccine and treatment candidates and the
company's strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such
forward-looking statements by terminology such as "anticipate," "intend," "believe,"
"estimate," "plan," "seek," "project," or "expect," "may,"
"will," "would," "could," "potential," "intend," or
"should," the negative of these terms or similar expressions. Forward-looking statements are based on management's
current beliefs and assumptions and on information currently available to the company. However, these forward-looking statements are
not a guarantee of the company's performance, and you should not place undue reliance on such statements. Forward-looking
statements are subject to many risks, uncertainties and other variable circumstances, including negative worldwide economic
conditions and ongoing instability and volatility in the worldwide financial markets, ability to obtain funding, ability to conduct
current and future preclinical studies and clinical trials, the timing, expense and uncertainty of regulatory approval, reliance on
third parties and collaboration partners, ability to commercialize products, ability to manufacture any products, possible changes
in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation
in the company's industry, the effects of the COVID-19 pandemic on the company's business and results of operations,
ability to manage growth, reliance on key personnel, reliance on intellectual property protection, ability to provide for patient
safety, and fluctuations of operating results due to the effect of exchange rates or other factors. Such risks and uncertainties may
cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks
are outside of the company's control and could cause its actual results to differ materially from those it thought would
occur. The forward-looking statements included in this press release are made only as of the date hereof. The company does not
undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any
revisions to any such statements to reflect future events or developments, except as required by law.
For further information, please reference the company's reports
and documents filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting EDGAR on the SEC
website at www.sec.gov.